Positron emission tomography (PET)/MRI targeting prostate-specific membrane antigen (PSMA) could be an ideal technique to improve the accuracy of imaging-guided biopsies, combining the high sensitivity and specificity of PSMA-PET for PCa with the high anatomical contrast and spatial resolution of MRI [13–15]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.